Potassium and the Atrioventricular Node

2015 ◽  
pp. 329-338
Author(s):  
H. B. Zimmerman
Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S355
Author(s):  
Taylor Stewart Howard ◽  
Santiago O. Valdes ◽  
Wilson W. Lam ◽  
Christina Y. Miyake ◽  
Ellis Rochelson ◽  
...  

Author(s):  
Shigeki Kiuchi ◽  
Akino Usami ◽  
Tae Shimoyama ◽  
Fuminori Otsuka ◽  
Shigeto Suzuki ◽  
...  

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
L Wu ◽  
B Narasimhan ◽  
A.N Shah ◽  
Y.Y Zheng ◽  
K Bhatia ◽  
...  

Abstract Introduction Atrial fibrillation (AF) ablation and Atrioventricular Node (AVN) ablation are both important non-pharmacological therapy of AF. In spite of increased availability of AF ablation data, that of AVN ablation per se is limited. Method AF ablation was identified using ICD-9 procedure code with principle diagnosis of AF from United States National Inpatient Sample database 2005–2014. From procedure and diagnosis codes of pacemaker insertion followed by ablation, the cohort who underwent AVN ablation was identified. Patients hospitalization with any diagnosis of other type of arrythmia or epicardial ablation were excluded. Complications were defined as per the Agency for Health Care Research and Quality guideline. Results Total AF ablation was noted to increase from 2005- 2011, and declined steadily from 2011–2014. In contrast, the number of AVN ablations increased from 4505 cases to 5175 (Figure 1). AVN ablation were mainly performed in elderly patient (mean age 72), and increasingly in patient with higher Charlson Commobidity index (0.9 to 1.7)and higher CHA2DS2-VASc score (2.8 to 3.7) (Table 1). An increasing trend in procedure complications but no significant change in mortalitywere observed with AVN ablation. Progressive increase in the length of stay and the hospitalization cost were also observed over the years with AVN ablation. Conclusion AVN ablation is being performed at a steady volume, and increasingly in patients with multiple comorbidities. This trend although was not associated with increased mortality, it was associated with increased hospital complications. Funding Acknowledgement Type of funding source: None


2021 ◽  
Vol 26 ◽  
pp. 101018
Author(s):  
Shigeki Kiuchi ◽  
Akino Usami ◽  
Tae Shimoyama ◽  
Fuminori Otsuka ◽  
Shigeto Suzuki ◽  
...  

2021 ◽  
Vol 8 (6) ◽  
pp. 70
Author(s):  
Mathilde R. Rivaud ◽  
Michiel Blok ◽  
Monique R. M. Jongbloed ◽  
Bastiaan J. Boukens

The electrophysiological signatures of the myocardium in cardiac structures, such as the atrioventricular node, pulmonary veins or the right ventricular outflow tract, are established during development by the spatial and temporal expression of transcription factors that guide expression of specific ion channels. Genome-wide association studies have shown that small variations in genetic regions are key to the expression of these transcription factors and thereby modulate the electrical function of the heart. Moreover, mutations in these factors are found in arrhythmogenic pathologies such as congenital atrioventricular block, as well as in specific forms of atrial fibrillation and ventricular tachycardia. In this review, we discuss the developmental origin of distinct electrophysiological structures in the heart and their involvement in cardiac arrhythmias.


1998 ◽  
Vol 274 (3) ◽  
pp. H829-H845 ◽  
Author(s):  
Bum-Rak Choi ◽  
Guy Salama

The mechanisms responsible for atrioventricular (AV) delay remain unclear, in part due to the inability to map electrical activity by conventional microelectrode techniques. In this study, voltage-sensitive dyes and imaging techniques were refined to detect action potentials (APs) from the small cells comprising the AV node and to map activation from the “compact” node. Optical APs (124) were recorded from 5 × 5 mm (∼0.5-mm depth) AV zones of perfused rabbit hearts stained with a voltage-sensitive dye. Signals from the node exhibited a set of three spikes; the first and third ( peaks I and III) were coincident with atrial (A) and ventricular (V) electrograms, respectively. The second spike ( peak II) represented the firing of midnodal (N) and/or lower nodal (NH) cell APs as indicated by their small amplitude, propagation pattern, location determined from superimposition of activation maps and histological sections of the node region, dependence on depth of focus, and insensitivity to tetrodotoxin (TTX). AV delays consisted of τ1 (49.5 ± 6.59 ms, 300-ms cycle length), the interval between peaks I and II (perhaps AN to N cells), and τ2 (57.57 ± 5.15 ms), the interval between peaks II and III (N to V cells). The conductance time across the node was 10.33 ± 3.21 ms, indicating an apparent conduction velocity (ΘN) of 0.162 ± 0.02 m/s ( n = 9) that was insensitive to TTX. In contrast, τ1 correlated with changes in AV node delays (measured with surface electrodes) caused by changes in heart rate or perfusion with acetylcholine. The data provide the first maps of activation across the AV node and demonstrate that ΘN is faster than previously presumed. These findings are inconsistent with theories of decremental conduction and prove the existence of a conduction barrier between the atrium and the AV node that is an important determinant of AV node delay.


2003 ◽  
Vol 14 (5) ◽  
pp. 461-466 ◽  
Author(s):  
José Dizon ◽  
James Reiffel ◽  
John Kassotis ◽  
Ian Woollett ◽  
Hasan Garan

Sign in / Sign up

Export Citation Format

Share Document